<DOC>
	<DOCNO>NCT00189332</DOCNO>
	<brief_summary>Pilot study test efficacy 852A administer intravenously 3 time per week 12 week subject inoperable metastatic cutaneous melanoma .</brief_summary>
	<brief_title>Use 852A Metastatic Cutaneous Melanoma .</brief_title>
	<detailed_description />
	<mesh_term>Melanoma</mesh_term>
	<criteria>Advanced melanoma respond 1st line chemotherapy Histological evidence melanoma Measurable disease accord RECIST criterion ECOG performance status less equal 2 Life expectancy 6 month Normal organ bone marrow function define hematological serum chemistry limit Adequate contraception female childbearing potential Stage IV disease previously progress interferon treatment . Restriction therapies/medications certain timeframe prior enrollment study include : investigational drug , high dose corticosteroid , immunotherapy , immunosuppressive medication , radiotherapy drug know prolong QT interval and/or induce Torsades De Pointes History uncontrolled seizure disorder Uncontrolled coagulation disorder . History evidence myocardial ischemia , congestive heart failure arrythmias require treatment past 6 month History uncontrolled intercurrent chronic illness Concurrent malignancy . Brain metastasis . HIV positive . Prolonged QTc interval Uncontrolled intercurrent chronic illness . Pregnant lactating woman</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2008</verification_date>
	<keyword>Oncology</keyword>
	<keyword>Melanoma</keyword>
</DOC>